BR112021023931A2 - Método para selecionar um sistema de barreira de pele adequado para bebês e crianças pequenas - Google Patents

Método para selecionar um sistema de barreira de pele adequado para bebês e crianças pequenas

Info

Publication number
BR112021023931A2
BR112021023931A2 BR112021023931A BR112021023931A BR112021023931A2 BR 112021023931 A2 BR112021023931 A2 BR 112021023931A2 BR 112021023931 A BR112021023931 A BR 112021023931A BR 112021023931 A BR112021023931 A BR 112021023931A BR 112021023931 A2 BR112021023931 A2 BR 112021023931A2
Authority
BR
Brazil
Prior art keywords
infants
selecting
young children
skin barrier
barrier system
Prior art date
Application number
BR112021023931A
Other languages
English (en)
Other versions
BR112021023931A8 (pt
Inventor
Elea Greugny
N Stamatas Georgios
Jalil Bensaci
Thierry Oddos
Original Assignee
Johnson & Johnson Consumer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson Consumer Inc filed Critical Johnson & Johnson Consumer Inc
Publication of BR112021023931A2 publication Critical patent/BR112021023931A2/pt
Publication of BR112021023931A8 publication Critical patent/BR112021023931A8/pt

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/44—Detecting, measuring or recording for evaluating the integumentary system, e.g. skin, hair or nails
    • A61B5/441—Skin evaluation, e.g. for skin disorder diagnosis
    • A61B5/445—Evaluating skin irritation or skin trauma, e.g. rash, eczema, wound, bed sore
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/75—Anti-irritant

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Data Mining & Analysis (AREA)
  • Primary Health Care (AREA)
  • Databases & Information Systems (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Absorbent Articles And Supports Therefor (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)

Abstract

método para selecionar um sistema de barreira de pele adequado para bebês e crianças pequenas. a presente invenção se refere a um método para selecionar um sistema de barreira de pele adequado para bebês e crianças pequenas.
BR112021023931A 2019-05-29 2020-05-28 Método para selecionar um sistema de barreira de pele adequado para bebês e crianças pequenas BR112021023931A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/425,283 US11229595B2 (en) 2019-05-29 2019-05-29 Skin barrier preparation and method therefor
PCT/IB2020/055077 WO2020240466A1 (en) 2019-05-29 2020-05-28 A method of selecting a skin barrier system suitable for infants and young children

Publications (2)

Publication Number Publication Date
BR112021023931A2 true BR112021023931A2 (pt) 2022-01-18
BR112021023931A8 BR112021023931A8 (pt) 2022-09-27

Family

ID=71083672

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021023931A BR112021023931A8 (pt) 2019-05-29 2020-05-28 Método para selecionar um sistema de barreira de pele adequado para bebês e crianças pequenas

Country Status (9)

Country Link
US (1) US11229595B2 (pt)
EP (1) EP3977484A1 (pt)
KR (1) KR20220012945A (pt)
CN (1) CN113874953A (pt)
AU (1) AU2020284714A1 (pt)
BR (1) BR112021023931A8 (pt)
CA (1) CA3140760A1 (pt)
MX (1) MX2021014570A (pt)
WO (1) WO2020240466A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023144701A1 (en) 2022-01-28 2023-08-03 Johnson & Johnson Consumer Inc. Biomarkers predictive of atopic dermatitis
WO2023194839A1 (en) 2022-04-04 2023-10-12 Donnelly Window of opportunity skin treatment regimen and composition for preventing the onset of or treating atopic dermatitis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2394612A1 (en) 2000-01-20 2001-07-26 The Procter & Gamble Company Antimicrobial compositions
US8150501B2 (en) * 2009-03-26 2012-04-03 Johnson & Johnson Consumer Companies, Inc. Method for measuring skin erythema
FR2993282B1 (fr) 2012-07-13 2017-11-10 Expanscience Lab Procede d'identification de marqueurs moleculaires de la peau d'enfant
WO2014028568A1 (en) 2012-08-15 2014-02-20 The Procter & Gamble Company Systems, models and methods for identifying and evaluating skin-active agents effective for treating an array of skin disorders
FR3019186B1 (fr) 2014-03-31 2019-06-07 Laboratoires Expanscience Procedes d'evaluation des effets deleteres de l'urine sur la peau d'enfant
FR3045669B1 (fr) 2015-12-16 2019-04-05 Laboratoires Expanscience Procedes d'evaluation des effets de la deshydratation sur la peau d'enfant
US20180185255A1 (en) 2017-01-05 2018-07-05 The Procter & Gamble Company Method of Selecting Mild Skin Cleansers
US11744905B2 (en) * 2018-01-05 2023-09-05 Johnson & Johnson Consumer Inc. Skin barrier preparation and method therefor

Also Published As

Publication number Publication date
EP3977484A1 (en) 2022-04-06
KR20220012945A (ko) 2022-02-04
AU2020284714A1 (en) 2021-12-16
WO2020240466A1 (en) 2020-12-03
US11229595B2 (en) 2022-01-25
MX2021014570A (es) 2022-01-11
CA3140760A1 (en) 2020-12-03
BR112021023931A8 (pt) 2022-09-27
CN113874953A (zh) 2021-12-31
US20200375888A1 (en) 2020-12-03

Similar Documents

Publication Publication Date Title
BR112020013593A8 (pt) Preparação de barreira da pele e método para a mesma
BR112016013562A2 (pt) Anticorpos anti-tau(ps422) humanizados, seus usos, e formulações farmacêuticas
BR112018006243A2 (pt) formas de cristal de mononucleotídeo de beta-nicotinamida
CO2018004321A2 (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
BR112018008901A2 (pt) formulações subcutâneas de anticorpos anti-cd 38 e seus usos
BR112018074056A2 (pt) composições e métodos relacionados a construtos de fc manipulados
MA44780A (fr) Préparation contenant un anticorps
CO2019002252A2 (es) Variantes de alfa-glucosidasa ácida y usos de las mismas
BR112017012344A2 (pt) anticorpos anti-c10orf54 e usos dos mesmos
MA40688A (fr) Anticorps humains contre la protéine de pic monoclonal du coronavirus du syndrome respiratoire du moyen-orient
UA116999C2 (uk) Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить
CL2019000610A1 (es) Variantes de alfa-glucosidasa ácida y usos de las mismas.
MA41375A (fr) Anticorps igg bispécifiques et leurs procédés de préparation
CL2014000491A1 (es) Anticuerpos monoclonales neutralizantes de las exotoxinas tcda y/o tcdb de clostridium difficile; composición farmacéutica que los comprende; y uso para tratar infección por c. difficile.
BR112017015880A2 (pt) anticorpos, usos e métodos
BR112021023931A2 (pt) Método para selecionar um sistema de barreira de pele adequado para bebês e crianças pequenas
CY1120718T1 (el) Αντι-αναρροϊκη συνθεση που διατηρει την κινητικοτητα του εντερου
AR109376A1 (es) FORMULACIONES DE g-HIDROXIBUTIRATO DE LIBERACIÓN MODIFICADA
EA201591266A1 (ru) Немолочные рецептуры
CL2017000937A1 (es) Indicador de humedad quimioluminiscente para productos absorbentes.
ECSP19008417A (es) Anticuerpos con inmunogenicidad baja y usos de estos
DK3680127T3 (da) Barnefastholdelsessystem
BR112018009004A8 (pt) conjugados anti-cd3-folato e seus usos
BR112017008097A2 (pt) método para tratar condições oculares
DK3111249T3 (da) Lasertranspondersystem og fremgangsmåde til at afbryde avanceret hastighedsmålende lidars

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: CHENANGO ZERO LLC (US)

B25A Requested transfer of rights approved

Owner name: CHENANGO ONE LLC (US) ; CHENANGO TWO LLC (US)

B25A Requested transfer of rights approved

Owner name: CHENANGO ONE LLC (US) ; CURRAHEE HOLDING COMPANY INC. (US)

B25D Requested change of name of applicant approved

Owner name: CHENANGO ONE LLC (US) ; JOHNSON AND JOHNSON CONSUMER INC. (US)

B25A Requested transfer of rights approved

Owner name: CHENANGO ONE LLC (US) ; JOHNSON AND JOHNSON CONSUMER INC. (US)

B25D Requested change of name of applicant approved

Owner name: CHENANGO ONE LLC (US) ; JOHNSON AND JOHNSON CONSUMER INC. (US)